Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023GlobeNewsWire • 04/27/23
Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitorGlobeNewsWire • 04/25/23
Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate UpdateGlobeNewsWire • 04/20/23
Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023GlobeNewsWire • 04/18/23
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTechGlobeNewsWire • 04/04/23
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161GlobeNewsWire • 03/16/23
Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral ResearchGlobeNewsWire • 03/14/23
Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate UpdateGlobeNewsWire • 03/02/23
Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate UpdateGlobeNewsWire • 02/16/23
Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus InfectionGlobeNewsWire • 12/13/22
Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/09/22
Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®GlobeNewsWire • 11/01/22
Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022GlobeNewsWire • 10/31/22